CAS 1234703-40-2|LY2608204

Introduction：Basic information about CAS 1234703-40-2|LY2608204, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. LY2608204 BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Synonyms

Common Name	LY2608204
CAS Number	1234703-40-2	Molecular Weight	559.807
Density	1.4±0.1 g/cm3	Boiling Point	/
Molecular Formula	C₂₈H₃₇N₃O₃S₃	Melting Point	/
MSDS	/	Flash Point	/

Names

Name	(1R,2S)-2-cyclohexyl-1-(4-cyclopropylsulfonylphenyl)-N-[5-(2-pyrrolidin-1-ylethylsulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamide
Synonym	More Synonyms

LY2608204 BiologicalActivity

Description	LY2608204 is a activator of glucokinase (GK) with EC50 of 42 nM.IC 50 value: 42 nM (EC50)Target: glucokinasein vitro: LY2608204 activates glucokinase (GK) with EC50 of 42 nM at 10 mM glucose with a concentration dependent manner at lower glucose concentrations. LY2608204 also stimulates glucose metabolism in rat insulinoma INS1-E cells with EC50 of 579 nM.in vivo: LY2608204 decreases plasma glucose in a dose-dependent manner at both fasted and postprandial glucose levels. A maximal lowering of glucose AUC versus the untreated control group is observed with the high dose (30 mg/kg) and represents a 42% decrease. Interpolation of the data show that a 20% glucose AUC decrease occurs at an average LY2608204 concentration of 99 ng/mL (179 nM) in plasma, corresponding to a 6.9 mg/kg LY2608204 dose. The in vivo blood brain barrier permeability of LY2608204 results in a mean brain/plasma ratio of 0.17 five minutes post-dose with a mean total brain level of 0.539 nmol/g.Clinical trail:
Related Catalog	Signaling Pathways >>Metabolic Enzyme/Protease >>GlucokinaseResearch Areas >>Metabolic Disease

Description

LY2608204 is a activator of glucokinase (GK) with EC50 of 42 nM.IC 50 value: 42 nM (EC50)Target: glucokinasein vitro: LY2608204 activates glucokinase (GK) with EC50 of 42 nM at 10 mM glucose with a concentration dependent manner at lower glucose concentrations. LY2608204 also stimulates glucose metabolism in rat insulinoma INS1-E cells with EC50 of 579 nM.in vivo: LY2608204 decreases plasma glucose in a dose-dependent manner at both fasted and postprandial glucose levels. A maximal lowering of glucose AUC versus the untreated control group is observed with the high dose (30 mg/kg) and represents a 42% decrease. Interpolation of the data show that a 20% glucose AUC decrease occurs at an average LY2608204 concentration of 99 ng/mL (179 nM) in plasma, corresponding to a 6.9 mg/kg LY2608204 dose. The in vivo blood brain barrier permeability of LY2608204 results in a mean brain/plasma ratio of 0.17 five minutes post-dose with a mean total brain level of 0.539 nmol/g.Clinical trail:

Related Catalog

Signaling Pathways >>Metabolic Enzyme/Protease >>GlucokinaseResearch Areas >>Metabolic Disease

Chemical & Physical Properties

Density	1.4±0.1 g/cm3
Molecular Formula	C₂₈H₃₇N₃O₃S₃
Molecular Weight	559.807
Exact Mass	559.199707
PSA	144.78000
LogP	4.97
Index of Refraction	1.658
InChIKey	QIIVJLHCZUTGSD-CUBQBAPOSA-N
SMILES	O=C(Nc1ncc(SCCN2CCCC2)s1)C1(c2ccc(S(=O)(=O)C3CC3)cc2)CC1C1CCCCC1

Safety Information

Hazard Codes	Xi

Synonyms

(1R,2S)-2-cyclohexyl-1-[4-(cyclopropanesulfonyl)phenyl]-N-(5-{[2-(pyrrolidin-1-yl)ethyl]sulfanyl}-1,3-thiazol-2-yl)cyclopropane-1-carboxamide

(1R,2S)-2-cyclohexyl-1-(4-cyclopropanesulfonylphenyl)cyclopropanecarboxylic acid [5-(2-pyrrolidin-1-ylethylsulfanyl)thiazol-2-yl]amide

(1R,2S)-2-Cyclohexyl-1-[4-(cyclopropylsulfonyl)phenyl]-N-(5-{[2-(1-pyrrolidinyl)ethyl]sulfanyl}-1,3-thiazol-2-yl)cyclopropanecarboxamide

Cyclopropanecarboxamide, 2-cyclohexyl-1-[4-(cyclopropylsulfonyl)phenyl]-N-[5-[[2-(1-pyrrolidinyl)ethyl]thio]-2-thiazolyl]-, (1R,2S)-

LY2608204

Recommended......